Table 5 Efficacy strength measures at baseline and follow-up. Values are mean (SD) Newtons, P=p value, d=effect size
From: Nonsurgical management of hallux valgus: findings of a randomised pilot and feasibility trial
|  | Control group (n = 14) | Intervention group (n = 14) | Adjusted mean difference (95% CI)a | P | d |
|---|---|---|---|---|---|
Ankle dorsiflexion | |||||
 Baseline | 108.0 (29.4) | 98.6 (28.9) |  |  |  |
 12 weeks | 111.8 (31.4) | 127.5 (23.7) | 20.6 (-1.3 to 42.5) | 0.064 | 0.71 |
Ankle plantarflexion | |||||
 Baseline | 111.9 (26.9) | 99.5 (25.7) |  |  |  |
 12 weeks | 125.5 (33.9) | 137.9 (30.2) | 19.7 (-9.4 to 48.8) | 0.172 | 0.61 |
Ankle inversion | |||||
 Baseline | 83.7 (29.8) | 69.6 (16.9) |  |  |  |
 12 weeks | 93.8 (33.9) | 94.6 (19.5) | 15.3 (-3.4 to 33.9) | 0.105 | 0.56 |
Ankle eversion | |||||
 Baseline | 62.3 (24.3) | 62.7 (17.0) |  |  |  |
 12 weeks | 80.3 (24.4) | 92.0 (15.3) | 12.9 (-2.2 to 27.9) | 0.089 | 0.61 |
Lesser toe plantarflexion | |||||
 Baseline | 40.0 (13.8) | 35.2 (12.8) |  |  |  |
 12 weeks | 40.0 (13.1) | 40.4 (8.5) | 1.6 (-8.3 to 11.5) | 0.741 | 0.14 |
Hallux plantarflexion | |||||
 Baseline | 42.2 (10.7) | 37.4 (11.5) |  |  |  |
 12 weeks | 42.9 (17.8) | 55.1 (18.8) | 12.9 (-2.7 to 28.6) | 0.101 | 0.68 |